The U.S. Food and Drug Administration has granted approval to Takeda Pharmaceutical Co Ltd for an oral treatment designed to address narcolepsy type 1, the agency announced on Wednesday. The medication, marketed under the name Orzeyful, is the first approved therapy that targets the full spectrum of symptoms tied to the rare sleep disorder by acting on the orexin system.
What narcolepsy type 1 is
Narcolepsy type 1 is caused by the loss of brain cells that produce orexin, a neurotransmitter that plays a key role in regulating wakefulness, sleep cycles and muscle tone. According to Takeda, the condition affects roughly 120,000 people in the United States and produces a range of symptoms, including excessive daytime sleepiness, sudden episodes of muscle weakness known as cataplexy, cognitive disturbances and interrupted nighttime sleep.
How Orzeyful works and the evidence
Orzeyful is administered twice daily as an oral capsule and is designed to directly counteract the diminished orexin signaling responsible for narcolepsy type 1. The FDA’s approval drew on results from two clinical studies in which patients receiving Orzeyful demonstrated greater improvements in maintaining daytime wakefulness compared with placebo recipients.
The agency noted that, until this approval, there had been no medicine specifically approved to treat narcolepsy type 1 as a unified disorder and that no prior approved therapy acted on the orexin system.
Regulatory next steps and patient access
Takeda said the Drug Enforcement Administration is currently reviewing whether Orzeyful should be classified as a controlled substance. The company expects the DEA to issue a scheduling decision within 90 days. Once that classification is established, Orzeyful will be distributed through a specialty pharmacy to U.S. healthcare providers and patients, Takeda added.
Note on market identifiers: Takeda is listed in U.S. markets under the ADR ticker TAK.